Polyrizon Ltd.PLRZ
Price (close)
$10.51
Market cap
$25.2M
P/E
—
Revenue (FY)
—
Net income
-$3.3M
Dividend yield
—
1-year total return
65.3%
Net margin
—
Revenue growth
—
Debt / equity
—
What Polyrizon Ltd. does.
are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form
of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses
and allergens from contacting the nasal epithelial tissue. Our C&C, hydrogel technology, comprised of a mixture of naturally occurring
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | — | -$779,000 | -$600,000 | -$1.5M | -$3.3M |
| Free cash flow | — | -$1.1M | — | — | -$4.5M |
More on PLRZ.
- Polyrizon Ltd. summary
- Polyrizon Ltd. financial statements
- Polyrizon Ltd. key metrics
- Polyrizon Ltd. health scores and style box
- Polyrizon Ltd. earnings
- Polyrizon Ltd. dividends
- Polyrizon Ltd. valuation
- Polyrizon Ltd. ownership and insiders
- Polyrizon Ltd. peers
Figures from Polyrizon Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.